1225 CHARACTERIZATION OF VIRAL RESISTANCE MUTATIONS IN GENOTYPE 1 HCV PATIENTS RECEIVING COMBINATION THERAPY WITH A PROTEASE INHIBITOR AND A POLYMERASE INHIBITOR WITH OR WITHOUT RIBAVIRIN